LIF, Green Public Procurement and follow-ups

As I have mentioned earlier here at the blog (see blog post from Oct 19 and from Nov 29), I start working part-time at the LIF Office today. And perhaps I should take it as ”a good sign” that an issue I have worked upon for several years (both within Pfizer and in LIF’s environmental committee), namely green criteria in the tender business process, was highlighted in NyTeknik yesterday. The article shows great progress in the willingness from Swedish County Councils to start evaluate, and follow-up, green criteria. As you may know if you have read my blog post on tenders and public procurement previously (see for instance the blog posts from Sept 8, and May 26), I regard follow-ups as extremely critical for the process to work satisfactory:

Quote from blog post May 26: ”And I restated LIF’s position: We welcome requirements, if they are fair, reasonable and in line with the public procurement regulations, e.g. LOU (Lagen om Offentlig Upphandling). LIF’s position also clearly states that requirements should be followed-up, otherwise “honest and serious” companies may suffer compared with “cheaters”.

Green criteria in the public procurement of pharmaceuticals have been developed by the Swedish Environmental Management Council (MSR) in collaboration with all relevant stakeholders in the sector. Those criteria, and all good discussions leading forward to the development of the criteria, will be very valuable during 2012 when green economic incentives and green criteria within the framework of the pricing and reimbursement system are being discussed. One of my main tasks working at the LIF Office during 2012 will be to connect with Sofia Wallström in her review and to establish a model of green criteria and evaluation on which green economic incentives could be based. My task here is the work related to action item 7.2 in the National Pharmaceutical Strategy, and Sofia Wallström’s task is the one described in action item 7.1:

7.1. Investigate if the environmental aspects should be considered when decisions on subsidy for a pharmaceutical are decided (Lead: Ministry of Health and Social Affairs): Review of possibilities to – within the context of the national reimbursement system – increasingly take environmental considerations.
7.2. Encourage voluntary control of emissions from pharmaceutical factories (Lead: LIF): Introduction of a voluntary environmental labeling of pharmaceutical products.

I am looking forward to an interesting year 2012!

Kommentera

E-postadressen publiceras inte. Obligatoriska fält är märkta *